OPtical Frequency Domain Imaging Versus INtravascular Ultrasound in Percutaneous Coronary InterventiON - OPINION Imaging
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01873222 |
|
Recruitment Status :
Completed
First Posted : June 10, 2013
Last Update Posted : July 14, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Coronary Artery Disease | Device: OFDI-guided PCI & IVUS Device: IVUS-guided PCI & OFDI | Phase 3 |
Optical frequency domain imaging (OFDI) is a novel, high resolution intravascular imaging modality. Intravascular ultrasound (IVUS) is a widely used conventional imaging modality for achieving optimal stent deployment.
This study is the sub-study of OPINION Trial. (UMIN000010580) The aim of this study is to evaluate how OFDI or IVUS imaging technology influence to the Percutaneous Coronary Intervention (PCI) strategy.
We will enroll the first 100 patients who have enrolled in the main-study of OPINION trial.(UMIN000010580). We will assess lesions by the other device in addition to the assigned device in the main study at the time of post-PCI.
We will then assess lesions by OFDI at a 8-month follo-up.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 106 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON - OPINION Imaging |
| Study Start Date : | June 2013 |
| Actual Primary Completion Date : | July 2016 |
| Actual Study Completion Date : | July 2016 |
| Arm | Intervention/treatment |
|---|---|
Experimental: OFDI-guided PCI & IVUS
|
Device: OFDI-guided PCI & IVUS
Other Names:
|
Active Comparator: IVUS-guided PCI & OFDI
|
Device: IVUS-guided PCI & OFDI
Other Names:
|
- Minimum stent area by OFDI [ Time Frame: at just after the PCI ]The investigators will assess "Minimum stent area" by OFDI at post-PCI.
- Frequency of malapposed struts [ Time Frame: at just after the PCI ]The investigators will assess "Frequency of malapposed struts" by OFDI at post-PCI.
- Dissection [ Time Frame: at just after the PCI ]The investigators will assess "Dissection" by OFDI at post-PCI.
- Minimum stent area by IVUS [ Time Frame: at just after the PCI ]The investigators will assess "Minimum stent area" by IVUS at post-PCI.
- Frequency of uncovered struts [ Time Frame: 8 months after PCI ]The investigators will assess "Frequency of uncovered struts" by OFDI at 8 months after PCI.
- Minimum lumen area [ Time Frame: 8-month follow-up after PCI ]The investigators will assess "Minimum lumen area by OFDI at 8 months after PCI.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients participating in the OPINION Trial
- Patients who has provided written informed consent
Exclusion Criteria:
- Ineligible patients according to the investigator's judgment
- Inability or unwillingness to perform required follow up procedures
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01873222
| Japan | |
| Wakayama Medical University | |
| Wakayama, Wakayama Prefecture, Japan, 641-8510 | |
| Principal Investigator: | Takashi Akasaka, MD, PhD | Wakayama Medical University |
| Responsible Party: | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan |
| ClinicalTrials.gov Identifier: | NCT01873222 |
| Other Study ID Numbers: |
TRICVD1311 UMIN000010581 ( Registry Identifier: UMIN Clinical Trial Registry ) |
| First Posted: | June 10, 2013 Key Record Dates |
| Last Update Posted: | July 14, 2016 |
| Last Verified: | July 2016 |
|
Coronary Artery Disease Percutaneous Coronary Intervention Optical Frequency Domain Imaging Intravascular Ultrasound |
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Sirolimus Umirolimus |
Anti-Inflammatory Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antineoplastic Antineoplastic Agents Antifungal Agents |

